Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Int J Angiol ; 29(4): 223-228, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33268972

ABSTRACT

Coronary computed tomography angiography (CCTA) offers high-resolution anatomic characterization of the coronary vasculature but may be suboptimal for lesions dependent on real-time visualization of flow including chronic total occlusion (CTO). In CTOs, heavy calcification and distal vessel opacification from collateralization may confound luminal assessment. Several studies have examined the role of CCTA in characterizing known CTOs to guide percutaneous coronary intervention (PCI). However, the efficacy of CCTA in the de novo diagnosis of CTOs prior to coronary angiography (CAG) has not been demonstrated. A total of 233 consecutive patients who presented for CAG within a 3-month period of having CCTA were retrospectively reviewed. Those patients with prior diagnosis of CTO or prior bypass of the occluded vessels were excluded. Sensitivity and specificity analysis of CCTA in identifying CTOs using CAG as the gold standard was performed. The prevalence of CTO was 21.11% in the population that met criteria for analysis ( n = 199). The sensitivity of CCTA in predicting CTO was 57.1%, while the specificity was 96.8%. The positive predictive value and negative predictive value of CCTA in detection of CTO were 82.8 and 89.4%, respectively. Our study shows that CCTA has excellent specificity but poor sensitivity in the detection of CTO thus limiting its clinical use in de novo diagnosis. Further studies to determine the effect of de novo CTO diagnosis on clinically important procedural factors, such as radiation exposure, contrast use, and need for repeat procedures, are warranted and may implicate a role for CCTA in this setting.

2.
J Cardiovasc Surg (Torino) ; 52(6): 877-85, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22051997

ABSTRACT

AIM: The aim of the present study was to investigate the relative importance of a wide array of patient demographic, procedural, anatomic and perioperative variables as potential risk factors for early saphenous vein graft (SVG) thrombosis after coronary artery bypass graft (CABG) surgery. METHODS: The patency of 611 SVGs in 291 patients operated on at four different hospitals enrolled in the Reduction in Graft Occlusion Rates (RIGOR) study was assessed six months after CABG surgery by multidetector computed tomography coronary angiography or clinically-indicated coronary angiography. The odds of graft occlusion versus patency were analyzed using multilevel multivariate logistic regression with clustering on patient. RESULTS: SVG failure within six months of CABG surgery was predominantly an all-or-none phenomenon with 126 (20.1%) SVGs totally occluded, 485 (77.3%) widely patent and only 16 (2.5%) containing high-grade stenoses. Target vessel diameter ≤ 1.5 mm (adjusted OR 2.37, P=0.003) and female gender (adjusted OR 2.46, P=0.01) were strongly associated with early SVG occlusion. In a subgroup analysis of 354 SVGs in which intraoperative graft blood flow was measured, lower mean flow was also significantly associated with SVG occlusion when analyzed as a continuous variable (adjusted OR 0.984, P=0.006) though not when analyzed dichotomously, <40 mL/min versus ≥ 40 mL/min (adjusted OR 1.86, P=0.08). CONCLUSION: Small target vessel diameter, female gender and low mean graft blood flow are significant risk factors for SVG thrombosis within six months of CABG surgery in patients on postoperative aspirin therapy. This information may be useful in guiding revascularization strategies in selected patients.


Subject(s)
Coronary Artery Bypass/adverse effects , Graft Occlusion, Vascular/etiology , Saphenous Vein/transplantation , Venous Thrombosis/etiology , Aged , Chi-Square Distribution , Coronary Angiography/methods , Coronary Circulation , Female , Graft Occlusion, Vascular/diagnostic imaging , Graft Occlusion, Vascular/physiopathology , Humans , Logistic Models , Male , Middle Aged , Odds Ratio , Predictive Value of Tests , Regional Blood Flow , Risk Assessment , Risk Factors , Saphenous Vein/diagnostic imaging , Saphenous Vein/physiopathology , Sex Factors , Time Factors , Tomography, X-Ray Computed , Treatment Outcome , United States , Vascular Patency , Venous Thrombosis/diagnostic imaging , Venous Thrombosis/physiopathology
3.
Cephalalgia ; 30(5): 528-34, 2010 May.
Article in English | MEDLINE | ID: mdl-19673910

ABSTRACT

We identified clinical, demographic and psychological predictive factors that may contribute to the development of chronic headache associated with mild to moderate whiplash injury [Quebec Task Force (QTF) ≤ II] and determined the incidence of this chronic pain state. Patients were recruited prospectively from six participating accident and emergency departments. While 4.6% of patients developed chronic headache attributed to whiplash injury according to the International Classification of Headache Disorders, 2nd edn criteria, 15.2% of patients complained about headache lasting > 42 days (QTF criteria). Predictive factors were pre-existing facial pain [odds ratio (OR) 9.7, 95% confidence interval (CI) 2.1, 10.4; P = 0.017], lack of confidence to recover completely (OR 5.5, 95% CI 2.0, 13.2; P = 0.005), sore throat (OR 5.0, 95% CI 1.5, 8.9; P = 0.013), medication overuse (OR 4.2, 95% CI 1.4, 12.3; P = 0.009), high Neck Disability Index (OR 4.0, 95% CI 1.3, 12.6; P = 0.019), hopelessness/anxiety (OR 3.8, 95% CI 1.3, 8.7; P = 0.024), and depression (OR 3.3, 95% CI 1.2, 9.4; P = 0.024). The lack of a control group limits the conclusions that can be drawn from this study. Identified predictors closely resemble those found in chronic primary headache disorders.


Subject(s)
Headache/epidemiology , Headache/etiology , Headache/psychology , Whiplash Injuries/complications , Whiplash Injuries/epidemiology , Whiplash Injuries/psychology , Accidents, Traffic , Adolescent , Adult , Aged , Chronic Disease , Female , Humans , Incidence , Male , Middle Aged , Surveys and Questionnaires , Young Adult
6.
Am J Manag Care ; 7(3): 261-6, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11258143

ABSTRACT

OBJECTIVE: To explore differences in expenditures for elderly patients with acute and chronic coronary artery disease according to the specialty of the principal care physician. STUDY DESIGN: Retrospective analysis of Medicare claims. PATIENTS AND METHODS: A total of 250,514 patients with coronary artery disease (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes 410-414) were drawn from a national random sample of 1992 Medicare expenditures. Patients were classified by the physician type with the highest number of Medicare Part B outpatient claims into a cardiologist group and a generalist group. The outcome was mean total expenditures, stratifying (1) by comorbidity as measured by the modified Charlson Index and (2) by severity defined as the proportion of patients with acute myocardial infarction or unstable angina. RESULTS: Those patients in the cardiologist group had lower comorbidity and higher severity than those in the generalist group. Overall mean expenditures were significantly higher for the cardiologist group than for the generalist group ($7658 vs $6047; P < .001). These differences in mean expenditures were evident at each level of comorbidity. However, when stratified by severity of diagnosis, differences were seen predominantly in those with acute diagnoses. For those with either acute myocardial infarction or unstable angina, the mean expenditures were higher for the cardiologist group than for the combined generalist group ($15,378 vs $12,260; P < .001); however, the mean expenditures for those with only chronic conditions were similar ($4856 vs $4745; P = .53). CONCLUSION: Expenditures were higher when cardiologists were the principal care physicians treating patients with acute disease but not chronic disease.


Subject(s)
Cardiology/economics , Coronary Disease/economics , Family Practice/economics , Health Expenditures/statistics & numerical data , Medicare/statistics & numerical data , Acute Disease , Aged , Chronic Disease , Comorbidity , Coronary Disease/complications , Coronary Disease/therapy , Health Services Research , Humans , Severity of Illness Index , United States
8.
Am J Hypertens ; 13(11): 1168-72, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11078176

ABSTRACT

Hypertensive patients with target organ damage are at increased cardiovascular risk, and should be treated most aggressively. The association between urinary albumin excretion and left ventricular hypertrophy (LVH) in prior studies is inconsistent, and has not been described using a single, random spot urine specimen. Therefore, we evaluated the association between the urinary albumin creatinine ratio (ACR) and left ventricular (LV) mass and also tested the hypothesis that a simple random, single-void urine ACR would identify high risk young, hypertensive, African-American men. We measured echocardiographic LV mass and a random spot urinary ACR in 109 untreated, hypertensive, young, inner city, African-American men. The mean age was 41 +/- 6 years and the mean blood pressure (BP) was 157 +/- 19/107 +/- 13 mm Hg. Microalbuminuria (ACR 30 to 300 mg/g) was present in 22% of subjects. The ACR is higher in the men with LVH than in the men without LVH (P < .05). Increased ACR is a predictor of increased LV mass index (P < .003) using multiple linear regression. An ACR >30 mg/g has a sensitivity of 33% and a specificity of 82% for the diagnosis of echocardiographic LVH. In conclusion, elevated random spot ACR is a marker of increased LV mass, independent of BP, in young urban African-American men with hypertension, and may help to determine the aggressiveness of antihypertensive therapy in this high-risk group.


Subject(s)
Albuminuria/metabolism , Black People , Creatinine/urine , Hypertrophy, Left Ventricular/diagnosis , Adolescent , Adult , Blood Pressure/physiology , Humans , Hypertension/ethnology , Hypertension/physiopathology , Hypertrophy, Left Ventricular/urine , Male , Middle Aged , Sensitivity and Specificity , Urban Health , Ventricular Function, Left/physiology
9.
Am Heart J ; 140(5): 785-91, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11054626

ABSTRACT

BACKGROUND: The reported mortality rate of peripartum cardiomyopathy (PPCM) is high, although the potential for spontaneous recovery of ventricular function is well established. The prevalence of myocarditis in PPCM has varied widely between studies. The purposes of this study were to define the long-term prognosis in a referral population of patients with PPCM, to determine the prevalence of myocarditis on endomyocardial biopsy in this population, and to identify clinical variables associated with poor outcome. METHODS: We analyzed clinical, echocardiographic, hemodynamic, and histologic features of 42 women with PPCM evaluated at our institution over a 15-year period. Each patient underwent an extensive evaluation, including echocardiography, endomyocardial biopsy, and right heart catheterization. Data were analyzed to identify features at initial examination associated with the combined end point of death or cardiac transplantation by the use of Kaplan-Meier survival curves and a Cox proportional hazards model. RESULTS: Three (7%) patients died and 3 (7%) patients underwent heart transplantation during a median follow-up of 8.6 years. Endomyocardial biopsy demonstrated a high prevalence of myocarditis (62%), but the presence or absence of myocarditis was not associated with survival. Of the prespecified variables assessed, only decreased left ventricular stroke work index was associated with worsened outcome. CONCLUSIONS: In patients with PPCM, (1) long-term survival is better than has been historically reported, (2) the prevalence of myocarditis is high, and (3) decreased left ventricular stroke work index is associated with worse clinical outcomes.


Subject(s)
Cardiomyopathies/mortality , Myocarditis/mortality , Puerperal Disorders/mortality , Adult , Biopsy , Cardiac Catheterization , Cardiomyopathies/diagnostic imaging , Cardiomyopathies/pathology , Cardiomyopathies/physiopathology , Confounding Factors, Epidemiologic , Echocardiography , Female , Hemodynamics , Humans , Maryland/epidemiology , Myocarditis/diagnostic imaging , Myocarditis/pathology , Myocarditis/physiopathology , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Puerperal Disorders/diagnostic imaging , Puerperal Disorders/pathology , Puerperal Disorders/physiopathology , Risk Factors , Survival Rate
10.
Circulation ; 101(19): 2239-46, 2000 May 16.
Article in English | MEDLINE | ID: mdl-10811589

ABSTRACT

BACKGROUND: The benefit of intravenous thrombolytic therapy in elderly patients with myocardial infarction is uncertain. There are no randomized trials of thrombolytic efficacy or observational studies of clinical effectiveness that focus specifically on the elderly. METHODS AND RESULTS: To determine whether thrombolytic therapy for elderly patients is associated with a survival advantage in a large observational database, we conducted a retrospective cohort study of 7864 Medicare fee-for-service patients aged 65 to 86 years with the primary discharge diagnosis of acute myocardial infarction who were admitted with clinical and ECG indications for thrombolytic therapy and no absolute contraindications. The study included all US acute care nongovernment hospitals without on-site angioplasty capability. Using proportional-hazards methods, we found that in a comprehensive multivariate model, there was a significant interaction (P<0.001) between age and the effect of thrombolytic therapy on 30-day mortality rates. For patients 65 to 75 years old, thrombolytic therapy was associated with a survival benefit, consistent with randomized trials. Among patients aged 76 to 86 years, thrombolytic therapy was associated with a survival disadvantage, with a 30-day mortality hazard ratio of 1.38 (95% CI 1. 12 to 1.71, P=0.003). For these patients, there was no benefit from thrombolytic therapy in any clinical subgroup. CONCLUSIONS: In nationwide clinical practice, thrombolytic therapy for patients >75 years old is unlikely to confer survival benefit and may have a significant survival disadvantage. Reperfusion research that is focused on elderly patients is urgently needed.


Subject(s)
Myocardial Infarction/therapy , Thrombolytic Therapy , Aged , Aged, 80 and over , Aging/physiology , Cohort Studies , Female , Humans , Injections, Intravenous , Male , Myocardial Infarction/mortality , Proportional Hazards Models , Retrospective Studies , Survival Analysis , Treatment Outcome
12.
J Immunol ; 163(10): 5497-504, 1999 Nov 15.
Article in English | MEDLINE | ID: mdl-10553076

ABSTRACT

Coxsackievirus infection causes myocarditis and pancreatitis in humans. In certain strains of mice, Coxsackievirus causes a severe pancreatitis. We explored the role of NO in the host immune response to viral pancreatitis. Coxsackievirus replicates to higher titers in mice lacking NO synthase 2 (NOS2) than in wild-type mice, with particularly high viral titers and viral RNA levels in the pancreas. Mice lacking NOS have a severe, necrotizing pancreatitis, with elevated pancreatic enzymes in the blood and necrotic acinar cells. Lack of NOS2 leads to a rapid increase in the mortality of infected mice. Thus, NOS2 is a critical component in the immune response to Coxsackievirus infection.


Subject(s)
Coxsackievirus Infections/enzymology , Coxsackievirus Infections/prevention & control , Nitric Oxide Synthase/physiology , Pancreatitis/enzymology , Pancreatitis/prevention & control , Acute Disease , Animals , Coxsackievirus Infections/genetics , Coxsackievirus Infections/mortality , Encephalitis, Viral/etiology , Enterovirus B, Human , Macrophages/enzymology , Mice , Mice, Inbred C57BL , Mice, Knockout , Myocarditis/etiology , Nitric Oxide Synthase/biosynthesis , Nitric Oxide Synthase/deficiency , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase Type II , Pancreas/enzymology , Pancreas/virology , Pancreatitis/genetics , Pancreatitis/mortality
13.
J Am Med Inform Assoc ; 6(3): 234-44, 1999.
Article in English | MEDLINE | ID: mdl-10332656

ABSTRACT

OBJECTIVE: Many hospitals are investing in computer-based provider order-entry (POE) systems, and providers' evaluations have proved important for the success of the systems. The authors assessed how physicians and nurses viewed the effects of one modified commercial POE system on time spent patients, resource utilization, errors with orders, and overall quality of care. DESIGN: Survey. MEASUREMENTS: Opinions of 271 POE users on medicine wards of an urban teaching hospital: 96 medical house officers, 49 attending physicians, 19 clinical fellows with heavy inpatient loads, and 107 nurses. RESULTS: Responses were received from 85 percent of the sample. Most physicians and nurses agreed that orders were executed faster under POE. About 30 percent of house officers and attendings or fellows, compared with 56 percent of nurses, reported improvement in overall quality of care with POE. Forty-four percent of house officers and 34 percent of attendings/fellows reported that their time with patients decreased, whereas 56 percent of nurses indicated that their time with patients increased (P < 0.001). Sixty percent of house officers and 41 percent of attendings/fellows indicated that order errors increased, whereas 69 percent of nurses indicated a decrease or no change in errors. Although most nurses reported no change in the frequency of ordering tests and medications with POE, 61 percent of house officers reported an increased frequency. CONCLUSION: Physicians and nurses had markedly different views about effects of a POE system on patient care, highlighting the need to consider both perspectives when assessing the impact of POE. With this POE system, most nurses saw beneficial effects, whereas many physicians saw negative effects.


Subject(s)
Attitude to Computers , Medical Records Systems, Computerized , Medication Systems, Hospital , Nurses , Physicians , Data Collection , Hospitals, Teaching , Humans , Patient Care
14.
N Engl J Med ; 340(21): 1640-8, 1999 May 27.
Article in English | MEDLINE | ID: mdl-10341277

ABSTRACT

BACKGROUND: Patients with chest pain thought to be due to acute coronary ischemia are typically taken by ambulance to the nearest hospital. The potential benefit of field triage directly to a hospital that treats a large number of patients with myocardial infarction is unknown. METHODS: We conducted a retrospective cohort study of the relation between the number of Medicare patients with myocardial infarction that each hospital in the study treated (hospital volume) and long-term survival among 98,898 Medicare patients 65 years of age or older. We used proportional-hazards methods to adjust for clinical, demographic, and health-system-related variables, including the availability of invasive procedures, the specialty of the attending physician, and the area of residence of the patient (rural, urban, or metropolitan). RESULTS: The patients in the quartile admitted to hospitals with the lowest volume were 17 percent more likely to die within 30 days after admission than patients in the quartile admitted to hospitals with the highest volume (hazard ratio, 1.17; 95 percent confidence interval, 1.09 to 1.26; P<0.001), which resulted in 2.3 more deaths per 100 patients. The crude mortality rate at one year was 29.8 percent among the patients admitted to the lowest-volume hospitals, as compared with 27.0 percent among those admitted to the highest-volume hospitals. There was a continuous inverse dose-response relation between hospital volume and the risk of death. In an analysis of subgroups defined according to age, history of cardiac disease, Killip class of infarction, presence or absence of contraindications to thrombolytic therapy, and time from the onset of symptoms, survival at high-volume hospitals was consistently better than at low-volume hospitals. The availability of technology for angioplasty and bypass surgery was not independently associated with overall mortality. CONCLUSIONS: Patients with acute myocardial infarction who are admitted directly to hospitals that have more experience treating myocardial infarction, as reflected by their case volume, are more likely to survive than are patients admitted to low-volume hospitals.


Subject(s)
Hospitalization/statistics & numerical data , Hospitals/statistics & numerical data , Myocardial Infarction/mortality , Outcome Assessment, Health Care , Aged , Cardiology , Clinical Competence/statistics & numerical data , Cohort Studies , Female , Health Services Research , Humans , Male , Medicine , Multivariate Analysis , Myocardial Infarction/therapy , Quality of Health Care , Regression Analysis , Retrospective Studies , Specialization , Survival Analysis , United States
15.
Am J Cardiol ; 82(10): 1178-82, 1998 Nov 15.
Article in English | MEDLINE | ID: mdl-9832090

ABSTRACT

Patients with chronic disease may be excluded from capitated managed care plans due to higher than average expected costs. In an attempt to remedy this inequity, one type of risk adjustment technique proposes to set separate capitation rates for certain chronic illnesses, including coronary artery disease (CAD). Cardiologists, who increasingly are requested to accept capitation, will benefit from understanding the impact of using clinical factors as opposed to using demographic factors to set capitation rates. Using a 5% national random sample of the 1992 Medicare population, we determined mean annual expenditures and variation in expenditures of individuals with CAD. We compared the use of 2 demographic factors currently used for capitation rate adjustment (age and gender) with 2 factors not currently used--3-digit International Classification of Disease (ICD-9) code (a measure for severity) and Charlson index (a measure for comorbidity). Mean annual expenditures for individuals with CAD were more than double mean annual expenditures for the general Medicare population ($6,944 vs $3,247). Among individuals with CAD, mean expenditures of subgroups defined by both age and gender ranged from $6,205 to $7,724. In comparison, stratifying by measures of severity and comorbidity identified subgroups with lower and higher mean expenditures, producing a range of $1,702 to $19,959. Substantial variation of expenditures for individuals within subgroups defined by severity and comorbidity remained, with few patients having substantially higher expenditures than the rest. When capitation rates are set with the use of demographic factors alone, patients may be subjected to risk selection and physicians to financial loss. Using clinical measures may decrease the incentive for patient risk selection, but substantial financial risk to physicians would remain, because of a relatively few patients with high expenditures (or costs).


Subject(s)
Capitation Fee , Cardiology/economics , Coronary Disease/economics , Health Expenditures/statistics & numerical data , Managed Care Programs/economics , Medicare/economics , Aged , Aged, 80 and over , Coronary Disease/classification , Female , Humans , Male , Random Allocation , Risk Adjustment , Sampling Studies , United States
16.
Oncol Rep ; 5(6): 1555-60, 1998.
Article in English | MEDLINE | ID: mdl-9769405

ABSTRACT

Combined therapy of gemcitabine with interferons on patients with histologically confirmed metastatic renal cell carcinoma is reported. Patients had an unfavourable disease due to documented tumor progression after various interferon-alpha-based immunotherapy (26 weeks on average). The median number of metastatic sites was 6.1 per patient and 78% of the patients exhibited >/= 4 lesions. Nine evaluable patients received at least 6 doses of gemcitabine and 8 doses of interferon-gamma. Overall, therapy resulted in a remission rate of 15% (4 x partial response; 4 x minor response) for single measurable lesions (n=53). Remissions were more often found for lesions, that did not progress at baseline evaluation (n=30; OR: 20%), compared to 8.7% for sites in progression (n=23). However, as a result of therapy, 43.5% of the progressive lesions did not continue to progress. Although only one of nine patients finally overall achieved a minor remission and one patient a stable disease, the median time to tumor progression (6.1 months) and the median survival (13.5 months) was favourable. In conclusion, the combination of gemcitabine and interferon demonstrated cytotoxic and cytostatic effects on metastases of renal cell carcinoma at a tolerable toxicity, thus controlled clinical studies for first line therapy with gemcitabine and interferon are in progress.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Renal Cell/therapy , Deoxycytidine/analogs & derivatives , Interferon-alpha/therapeutic use , Interferon-gamma/therapeutic use , Kidney Neoplasms/therapy , Adult , Aged , Antineoplastic Agents/adverse effects , Carcinoma, Renal Cell/pathology , Combined Modality Therapy/adverse effects , Deoxycytidine/adverse effects , Deoxycytidine/therapeutic use , Female , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Interferon-gamma/adverse effects , Kidney Neoplasms/pathology , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Recombinant Proteins , Gemcitabine
17.
Am J Cardiol ; 81(9): 1144-51, 1998 May 01.
Article in English | MEDLINE | ID: mdl-9605057

ABSTRACT

This study tested the hypothesis that stroke patients without a cardiac source of embolism suspected by clinical examination can be risk stratified by transesophageal echocardiography. Forty ischemic stroke patients without atrial fibrillation, prosthetic valves, ejection fraction < 20%, or recent myocardial infarction underwent multiplane transesophageal echocardiography: 24 (designated high risk) had > or = 1 of the following: left heart thrombus, vegetation, mass or spontaneous echo contrast, mobile ascending aortic or arch debris, patent foramen ovale, atrial septal defect or aneurysm, mitral annular calcification, mitral valve thickening, prolapse or mitral valve strands. End points were death, recurrent stroke, transient ischemic attack, myocardial infarction or peripheral embolism. Thirty-eight patients (95%) (23 high, 15 low risk) were followed for 14 +/- 8 months: 9 (24%) died of vascular causes including 4 who had a cardiac cause of death and 5 who had fatal strokes. Eight had recurrent strokes (4 nonfatal) and 1 nonfatal myocardial infarction occurred. Cardiovascular survival was predicted by transesophageal echocardiography: survival rates were 92% (low risk) and 63% (high risk) at 24 months (p = 0.036). Left atrial enlargement was independently associated with death from stroke (fatal stroke occurred in 25% of those with atrial enlargement compared to 8% of those with normal atrial dimension, p < or = 0.03), as was left atrial spontaneous echo contrast (50% died vs 9% without contrast, p < or = 0.03). Left ventricular hypertrophy and aortic atherosclerosis were both associated with the risk of recurrent stroke (30% of patients with ventricular hypertrophy had recurrent stroke compared to 10% with normal wall thickness (p < or = 0.05); 30% with aortic atherosclerosis had a recurrent stroke compared to none with a normal aorta (p < or = 0.05). Thus, transesophageal echocardiography clearly identifies patients at a high risk for cardiovascular mortality and morbidity after stroke despite an unsuspected source of embolism by clinical examination.


Subject(s)
Cerebrovascular Disorders/diagnostic imaging , Cerebrovascular Disorders/mortality , Echocardiography, Transesophageal , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Morbidity , Predictive Value of Tests , Risk Assessment , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...